Cited by 52Neuroinflammation and Neurodegeneration MechanismsSingle-cell and spatial transcriptomicsParkinson's Disease Mechanisms and Treatments

Single-Cell Transcriptomics and In Situ Morphological Analyses Reveal Microglia Heterogeneity Across the Nigrostriatal Pathway

Open access
Uriarte Huarte, Oihane, Kyriakis, Dimitrios, Heurtaux, Tony, Pires-Afonso, Yolanda, Grzyb, Kamil, Halder, Rashi, Buttini, Manuel, Skupin, Alexander +2 more·2021·Frontiers in Immunology

Abstract

Microglia are the resident immune effector cells of the central nervous system (CNS) rapidly reacting to various pathological stimuli to maintain CNS homeostasis. However, microglial reactions in the CNS may also worsen neurological disorders. Hence, the phenotypic analysis of microglia in healthy tissue may identify specific poised subsets ultimately supporting or harming the neuronal network. This is all the more important for the understanding of CNS disorders exhibiting regional-specific and cellular pathological hallmarks, such as many neurodegenerative disorders, including Parkinson’s disease (PD). In this context, we aimed to address the heterogeneity of microglial cells in susceptible brain regions for PD, such as the nigrostriatal pathway. Here, we combined single-cell RNA-sequencing with immunofluorescence analyses of the murine nigrostriatal pathway, the most affected brain region in PD. We uncovered a microglia subset, mainly present in the midbrain, displaying an intrinsic transcriptional immune alerted signature sharing features of inflammation-induced microglia. Further, an in situ morphological screening of inferred cellular diversity showed a decreased microglia complexity in the midbrain when compared to striatum. Our study provides a resource for the identification of specific microglia phenotypes within the nigrostriatal pathway, which may be relevant in PD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.639613

Cites

79 of 79 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A common genetic cause of PD are mutations of the LRRK2 gene, which is predominantly expressed in the CNS by MF.

    “Specifically, a common genetic cause of PD are mutations of the leucine rich repeat kinase 2 (LRRK2) gene 73 which is predominantly expressed in the CNS by M F .”

    From Clonal hematopoiesis-associated motoric deficits caused by monocyte-derived microglia accumulating in aging mice (2025) · cites this paper as [73]

    The Introduction and Discussion discuss Parkinson’s disease and microglia, but do not address LRRK2 mutations or which CNS cells predominantly express LRRK2. Searches of our full-text copy for “LRRK2” and its expanded name found no relevant passage; the copy therefore cannot verify the attributed claim. (LLM, conf=0.75)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Uriarte Huarte, O., Kyriakis, D., Heurtaux, T., Pires-Afonso, Y., Grzyb, K., Halder, R., Buttini, M., Skupin, A., Mittelbronn, M., & Michelucci, A.
Affiliations
University of Luxembourg (LU)
Corresponding author
Michelucci, Alessandro
Venue
Frontiers in Immunology
Published
2021-03-29
Volume
12
Pages
639613-639613
ISSN
1664-3224 (ISSN-L)
OpenAlex
W3142593804
Cited by
52
References
79
Citations by year
2026: 3 · 2025: 12 · 2024: 11 · 2023: 9 · 2022: 14 · 2021: 2 · 2012: 1
FWCI
3.60
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Open Repository and Bibliography (University of Luxembourg) (submittedVersion, cc-by-nc-sa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Fonds National de la Recherche Luxembourg (PRIDE15/10675146/CANBIO, C14/BM/7975668/CaSCAD , INTER/DFG/17/11583046)
  • National Institutes of Health
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Single-cell and spatial transcriptomics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
Keywords
nigrostriatal pathway, Parkinson's disease, microglial phenotype, midbrain, striatum, microglial morphology, neurodegeneration, single-cell transcriptomics
MeSH terms
Animals, Corpus Striatum, Female, Inflammation, Mesencephalon, Neurons, Parkinson Disease, Phenotype, Transcription, Genetic, Sequence Analysis, RNA, Microglia, Mice, Single-Cell Analysis, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review